{"nctId":"NCT00097708","briefTitle":"Experimental Medication For the Treatment of Generalized Anxiety Disorder","startDateStruct":{"date":"2004-11"},"conditions":["Anxiety Disorder"],"count":511,"armGroups":[],"interventions":[{"name":"experimental anti-anxiety drug","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects 18 to 65 years of age will be eligible to participate if they satisfy the DSM-IV-TR criteria for the diagnosis of GAD.\n\nExclusion Criteria:\n\n* No other primary psychiatric diagnosis besides GAD.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HAM-A Total Score","description":"Hamilton Anxiety Rating Scale (HAM-A). Each of 14 symptoms categories is rated from 0=not present to 4=very severe. Numbers for all categories are summed to produce the total score. Total score ranges from 0=anxiety symptoms not present to 56=very severe anxiety symptoms across all 14 categories.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.9","spread":null},{"groupId":"OG001","value":"-15.7","spread":null},{"groupId":"OG002","value":"-12.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":171},"commonTop":["Somnolence","Headache","Fatigue","Dizziness","Nausea"]}}}